​

Shuttle Pharmaceuticals Stock (NASDAQ:SHPH)

OwnershipFinancialsChart

Previous Close

$0.71

52W Range

$0.50 - $6.75

50D Avg

$0.87

200D Avg

$2.22

Market Cap

$737.98K

Avg Vol (3M)

$892.71K

Beta

1.41

Div Yield

-

SHPH Company Profile

Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

9

IPO Date

Aug 31, 2022

Website

SHPH Performance

SHPH Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-11.92M$-7.70M$-5.89M
Net Income$-11.72M$-9.14M$-6.59M
EBITDA$-11.92M$-7.78M$-3.99M
Basic EPS$-7.16$-885.73$-0.41
Diluted EPS$-7.16$-885.73$-0.41

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
AKANAkanda Corp.
IMCCIM Cannabis Corp.
MSPRMSP Recovery, Inc.
BBLGBone Biologics Corporation
ISPCiSpecimen Inc.
RDHLRedHill Biopharma Ltd.
BIVIBioVie Inc.
HSCSHeartSciences Inc.